Updated 23 February 2017

Inhaled medication Afrezza approved to treat diabetes

A rapid-acting inhaled insulin called Afrezza has just been approved by the American FDA.


An inhaled medication, Afrezza (human insulin), has been approved by the U.S. Food and Drug Administration to treat adults with type 1 and type 2 diabetes.

The rapid-acting, inhaled insulin is designed to be used within 20 minutes of beginning a meal, the agency said.

Diabetes affects an estimated 3 million people in South Africa, including many more who haven't been diagnosed.

Serious complications could include heart disease, blindness and damage to the nerves and kidneys.

ReadHow to recognise diabetes complications

Afrezza's safety and effectiveness were evaluated in clinical studies involving more than 3,000 people, of whom about two-thirds had type 2 diabetes and the rest had type 1 diabetes.

The drug is not meant to replace long-acting insulin, and must be used in combination with long-acting insulin in people with type 1 disease, the FDA said. It should not be used to treat diabetic ketoacidosis or by smokers, the agency added.

Afrezza has a boxed label warning that users with chronic obstructive pulmonary disease (COPD) could develop a respiratory condition called acute bronchospasm.

The drug, therefore, shouldn't be used by people with COPD or other forms of chronic lung disease such as asthma or lung cancer, the FDA said.

The most common side effects of the drug are hypoglycemia (low blood sugar), cough and throat pain or irritation.

Read: All about TAK 875, the diabetes drug that doesn't affect blood sugar levels

The FDA said it ordered several post-approval studies to evaluate the drug's use among children and the potential risk of developing lung cancer.

Afrezza is manufactured by the US biotech company, MannKind Corp and according to Diabetimine they are in talks with pharmaceutical companies to find a distributor for the medication. It is thought that it would be available to diabetes patients early in 2015. 

Read more:

The latest on creating a bionic pancreas
A quick look at the different types of insulin
Treatment options for type 2 diabetes


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules